Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$4.36
$4.30
$1.78
▼
$5.75
$96.26M0.87452,470 shsN/A
Agenus Inc. stock logo
AGEN
Agenus
$8.30
-0.7%		$5.49
$2.71
▼
$8.85
$373.67M1.412.09 million shs483,158 shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$14.79
-4.5%		$13.77
$10.76
▼
$45.00
$362.36M-0.04130,052 shs33,035 shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$40.84
+3.0%		$35.17
$2.03
▼
$14.36
$383.81M1.1150,104 shs504,339 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
0.00%0.00%0.00%0.00%+43.89%
Agenus Inc. stock logo
AGEN
Agenus
+9.00%+11.02%+39.80%+145.16%+90.43%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
+5.09%-1.90%+22.64%-7.41%+41.20%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
+2.61%+8.07%+13.58%+46.27%+98.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$4.36
$4.30
$1.78
▼
$5.75
$96.26M0.87452,470 shsN/A
Agenus Inc. stock logo
AGEN
Agenus
$8.30
-0.7%		$5.49
$2.71
▼
$8.85
$373.67M1.412.09 million shs483,158 shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$14.79
-4.5%		$13.77
$10.76
▼
$45.00
$362.36M-0.04130,052 shs33,035 shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$40.84
+3.0%		$35.17
$2.03
▼
$14.36
$383.81M1.1150,104 shs504,339 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
0.00%0.00%0.00%0.00%+43.89%
Agenus Inc. stock logo
AGEN
Agenus
+9.00%+11.02%+39.80%+145.16%+90.43%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
+5.09%-1.90%+22.64%-7.41%+41.20%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
+2.61%+8.07%+13.58%+46.27%+98.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
1.80
Reduce$4.8811.81% Upside
Agenus Inc. stock logo
AGEN
Agenus
2.25
Hold$19.50134.94% Upside
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
2.78
Moderate Buy$40.86176.25% Upside
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ADVM, LYEL, AGEN, and NLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Agenus Inc. stock logo
AGEN
Agenus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
8/14/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$34.00
8/14/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/11/2026
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$30.00 ➝ $25.00
8/7/2026
Agenus Inc. stock logo
AGEN
Agenus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
8/6/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$36.00
7/30/2026
Agenus Inc. stock logo
AGEN
Agenus
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00 ➝ $14.00
7/22/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
7/17/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/13/2026
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$23.00 ➝ $30.00
6/16/2026
Agenus Inc. stock logo
AGEN
Agenus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/A$3.40 per shareN/A
Agenus Inc. stock logo
AGEN
Agenus
$114.20M3.27N/AN/A($4.57) per share-1.82
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$40K9,058.88N/AN/A$9.54 per share1.55
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$130.93M-$8.58N/AN/AN/AN/A-3,476.17%-152.07%N/A
Agenus Inc. stock logo
AGEN
Agenus
$120K$2.583.22N/AN/A69.33%-47.68%57.73%11/9/2026 (Estimated)
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$274.45M-$12.83N/AN/AN/A-920,285.25%-91.62%-70.50%11/10/2026 (Estimated)
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/AN/A-37.22%-30.91%N/A

Latest ADVM, LYEL, AGEN, and NLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
Agenus Inc. stock logo
AGEN
Agenus
$0.05-$0.01-$0.06-$0.01$34.00 million$34.52 million
8/6/2026Q2 2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$1.94-$1.9180+$0.0220-$1.92$0.00 million$0.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
0.65
0.65
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.34
0.34
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/A
5.36
5.36
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Agenus Inc. stock logo
AGEN
Agenus
61.46%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
66.05%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%

Insider Ownership

CompanyInsider Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
6.00%
Agenus Inc. stock logo
AGEN
Agenus
6.50%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
6.20%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
19022.08 million20.75 millionOptionable
Agenus Inc. stock logo
AGEN
Agenus
44045.02 million42.09 millionOptionable
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
27024.50 million22.99 millionOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
October 18, 2024  |  news.stocktradersdaily.comN
Neurogene concludes merger deal with Neoleukin Therapeutics
December 20, 2023  |  pharmaceutical-technology.comP
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
December 20, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/neoleukin-therapeutics-nasdaq-nltx-good-104958542.html?.tsrc=rss
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
December 14, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/neoleukin-therapeutics-announces-1-4-000000270.html?.tsrc=rss
Neoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Dates
December 4, 2023  |  benzinga.comhttps://www.benzinga.com/quote/NLTX/dividend
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
October 5, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/pre-market-movers-ortx-cmbm-grom-rsvr-femy-1032680947
Neoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
September 26, 2023  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2023-09/60192176-neoleukin-therapeutics-inc-neoleukin-therapeutics-announces-1-for-5-reverse-stock-split-399.htm
Neoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%
September 26, 2023  |  dhakatribune.comD
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
September 22, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/neoleukin-therapeutics-announces-1-5-120000211.html?.tsrc=rss
Investing in Neoleukin Therapeutics Inc. [NLTX]: What You Must Know
August 21, 2023  |  knoxdaily.comK
Neoleukin Therapeutics Recent Insider Activity
August 18, 2023  |  benzinga.comhttps://www.benzinga.com/news/23/08/33917086/neoleukin-therapeutics-recent-insider-activity
BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc
August 18, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/baker-bros-advisors-lp-reduces-010204096.html?.tsrc=rss
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCU
August 8, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/shareholder-investigation-halper-sadeh-llc-investigates-amnb-ccf-nltx-scu-1032525841
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX
August 1, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/shareholder-investigation-halper-sadeh-llc-investigates-ajx-den-freq-nltx-1032499213
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
July 28, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/redmile-group-llc-boosts-stake-013418995.html
Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm
July 26, 2023  |  benzinga.comhttps://www.benzinga.com/pressreleases/23/07/g33394151/moore-kuehn-encourages-amnb-scu-nltx-and-prds-investors-to-contact-law-firm
Analysts review Neoleukin Therapeutics Inc.’s rating
July 26, 2023  |  knoxdaily.comK
ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCF
July 24, 2023  |  kentuckytoday.comK
Baker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics
July 24, 2023  |  247wallst.comhttps://247wallst.com/investing/2023/07/24/baker-bros-advisors-now-owns-19-99-of-neoleukin-therapeutics/
An Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price Growth
July 19, 2023  |  knoxdaily.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Visa logo displayed beside a blue Visa-branded credit card with chip, near a smartphone on a dark surface.
Visa’s AI Opportunity Is Hiding in Every Transaction
By Sam Quirke | August 12, 2026
Neon Cloudflare shield blocking and channeling glowing data streams, symbolizing AI-driven cybersecurity traffic growth.
Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
By Thomas Hughes | August 7, 2026
Microsoft and Amazon logos displayed on a translucent digital panel in a server room with warning icons.
AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
By Ryan Hasson | August 4, 2026
Illuminated glass panel displaying the Okta logo in a dark server room and office setting.
Okta’s AI Tailwind Could Put This Forgotten Software Stock Back in Play
By Sam Quirke | August 19, 2026
Palo Alto Networks logo displayed on a dark wall in a data center flanked by illuminated server racks.
Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
By Chris Markoch | August 21, 2026
Adverum Biotechnologies stock logo

Adverum Biotechnologies NASDAQ:ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Agenus stock logo

Agenus NASDAQ:AGEN

$8.30 -0.06 (-0.72%)
As of 02:10 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Lyell Immunopharma stock logo

Lyell Immunopharma NASDAQ:LYEL

$14.79 -0.70 (-4.52%)
As of 01:56 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$40.84 +1.20 (+3.03%)
As of 08/25/2026

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas